Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects

被引:0
作者
Mohr, S
Keith, G
Rihn, B
机构
[1] Inst Natl Rech & Secur, F-54501 Vandoeuvre Les Nancy, France
[2] CNRS, IBMC, UPR 9002, F-67084 Strasbourg, France
[3] INSERM, Fac Pharm, U525 Equipe 4, F-54000 Nancy, France
关键词
asbestos; mesothelioma; mesothelium; molecular profiling; pathophysiology; pleura; transcriptome;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Asbestos is known as mutagenic and carcinogenic for human and is responsible for many pulmonary diseases including asbestosis, bronchogenic carcinoma and malignant pleural mesothelioma. Occupational exposure to asbestos is involved in 70-80% of all malignant pleural mesothelioma. The later presents a growing challenge for both researcher and clinician. The diagnosis of malignant pleural mesothelioma is difficult and the current treatments did not show significant improvement of the survival. The increasing incidence of malignant pleural mesothelioma, its gravity and its human, social and financial consequences are of high concern in public health. In this paper we summarize the so jar knowledge on cellular. molecular and pathophysiological events involved in genesis and development of malignant pleural mesothelioma. Finally, the paper also report recent data sourced from the study of malignant pleural mesothelioma transcriptome using high-throughput technologies such as gene expression array. These data should improve the accuracy of mesothelioma diagnosis and therapy.
引用
收藏
页码:959 / 976
页数:18
相关论文
共 170 条
  • [2] MESOTHELIAL CELL-PROLIFERATION - A NONSPECIFIC RESPONSE TO LUNG INJURY ASSOCIATED WITH FIBROSIS
    ADAMSON, IYR
    BAKOWSKA, J
    BOWDEN, DH
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1994, 10 (03) : 253 - 258
  • [3] Anbazhagan R, 1999, CANCER RES, V59, P5119
  • [4] RECOMBINANT INTERFERON-ALPHA-2B IN THE TREATMENT OF DIFFUSE MALIGNANT PLEURAL MESOTHELIOMA
    ARDIZZONI, A
    PENNUCCI, MC
    CASTAGNETO, B
    MARIANI, GL
    CINQUEGRANA, A
    MAGRI, D
    VERNA, A
    SALVATI, F
    ROSSO, R
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (01): : 80 - 82
  • [5] Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO
  • [6] 2-3
  • [7] AULT JG, 1995, CANCER RES, V55, P792
  • [8] Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine
    Baas, P
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (01) : 62 - 69
  • [9] Banaei A, 2000, OCCUP ENVIRON MED, V57, P488, DOI 10.1136/oem.57.7.488
  • [10] Bard M, 2002, PRESSE MED, V31, P406